Significant reduction in systolic blood pressure following renal artery stenting in patients with uncontrolled hypertension: Results from the HERCULES trial |
| |
| Authors: | Michael R Jaff DO Mark Bates MD Timothy Sullivan MD Jeffrey Popma MD Xingyu Gao MS Margo Zaugg RN BSN Patrick Verta MS Stat DVM MD |
| |
| Institution: | 1. The Vascular Center, Massachusetts General Hospital, Boston, Massachusetts;2. Department of Surgery, West Virginia University School of Medicine, Charleston Division, Charleston, West Virginia;3. Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, Minnesota;4. Department of Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts;5. Abbott Vascular, Santa Clara, California |
| |
| Abstract: | Background : Atherosclerotic renal artery stenosis (ARAS) causes hypertension (HTN) and threatens renal function (RF). The HERCULES Trial is a prospective, multicenter trial of renal stenting in patients with uncontrolled HTN and ARAS evaluating the safety and effectiveness of the RX Herculink Elite Renal Stent System (Abbott Vascular, Santa Clara, CA). Results : Mean systolic blood pressure (SBP) at baseline was 162 mm Hg. Nearly 70% of patients were receiving three or more antihypertensive medications (mean 3.4 medications per patient). Baseline serum creatinine was 1.2 ± 0.4 and 61.5% of subjects had estimated glomerular filtration <60. The restenosis rate was 10.5% at 9 months. The study device, procedure, and clinical success rates were 96.0, 99.2, and 98.0%, respectively. Freedom from major adverse events was 94.8%. At 9 months, the mean SBP significantly decreased (mean 145, paired t test P < 0.0001) after stenting with no change in medications. There was no correlation between SBP reduction and baseline BNP or BNP reduction. | |
| Keywords: | renal artery stenosis renovascular hypertension stents |
|
|
